Is there an association between liraglutide use and female breast cancer in a real-world setting?

ABSTRACT:

Background

Liraglutide is a human glucagon-like peptide-1 receptor agonist approved for treatment of adults with type 2 diabetes mellitus at a maximum dose of 1.8 mg/day (Victoza^®) and more recently at 3.0 mg/day for weight management (Saxenda^®). During the evaluation of liraglutide for approval in weight management, a minor imbalance in the numbers of reported breast neoplasms was observed, motivating the present study. Our objective was to quantify the association between liraglutide and incidence of breast cancer (BC) among women in a real-world setting.

Patients and methods

Women initiating liraglutide or other antidiabetic therapies and who were enrolled in a large US health plan (2010-2014) were included. Comparisons of BC incidence rates were mad

SUBMITTER: Funch D 

PROVIDER: S-EPMC6254592 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature